Recent Updates
Recently added Catalysts

ACZ885

Phase 3

Acute Gouty Arthritis Flares | Small molecule | Musculoskeletal |Novartis AG|Last Updated: Jul 9, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDDMC
Total Trials1
Total Enrollment136
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01470989β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)PHASE3 COMPLETED 136Nov 1, 2011May 1, 2013Jul 9, 202156 United States, Australia +7
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Incidence Rate (IR) of Adverse Events, Serious Adverse Events and Death Per 100 Patient-years in Participants
From start of the core studies (CACZ885H2357 [NCT01080131] and CACZ885H2361 [NCT01356602]) up to end of the current study (36 weeks)

Adverse events (AEs) were defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline,or, if present at baseline, appears to worsen. Serious adverse events (SAEs) were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards.

Secondary Endpoints
Number of New Flares Per Participant
From start of the core studies (CACZ885H2357 [NCT01080131] and CACZ885H2361 [NCT01356602]) up to end of the current study (36 weeks)
Patient's Assessment of Gout Pain Intensity in the Most Affected Joint
up to 7 days post-dose
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
canakinumabEXPERIMENTALcanakinumab 150 mg s.c.
Interventions
NameTypeDescription
ACZ885DRUGcanakinumab 150 mg s.c., given on demand upon new flares
Triamcinolone acetonide 40 mgDRUGParticipants received 40 mg intramuscular (IM)
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites56

Inclusion Criteria: * Patients who have completed the second extension studies CACZ885H2356E2 or CACZ885H2357E2 * Patients treated with canakinumab in the core studies or subsequent extensions Exclusion Criteria: \- Pregnant or nursing (lactating) women

Countries:United StatesAustraliaCanadaEstoniaGermanyLatviaLithuaniaRussiaUkraine
Unlock Eligibility Criteria